• Alvotech recently resubmitted Biologics License Applications to the U.S. FDA for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2 mg, after addressing manufacturing and quality concerns at its Reykjavik facility and responding to a recent cGMP surveillance inspection.
• The move, under its commercialization partnership with Teva, underscores Alvotech’s push to expand its U.S. biosimilar footprint while reinforcing upgraded quality systems and diversified manufacturing capacity.
• We’ll now examine how the FDA resubmissions, following extensive manufacturing quality enhancements, shape Alvotech’s investment narrative in the biosimilars space.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

What Is Alvotech's Investment Narrative?

For Alvotech, the core investment story is about whether it can turn an increasingly broad, partnered biosimilar portfolio into durable cash generation before its balance sheet tightens further. The latest FDA resubmissions for AVT05 and AVT06 fit squarely into that debate: they keep the prospect of five U.S. biosimilars by year end on the table and suggest the Reykjavik quality issues are being worked through, which matters directly for near term revenue and confidence in guidance. At the same time, the business is still loss making on a full year basis, carries expensive debt and has less than a year of cash runway, so execution risk around approvals, launches and manufacturing remains high. The share price rebound after the news hints that investors see the filing progress as material, but not definitive.

However, investors should also be aware of how Alvotech’s tight liquidity and leverage could shape outcomes. Alvotech's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates span roughly US$4 to over US$46, showing how far apart individual views sit. Against that backdrop, the FDA’s six month review of AVT05 and AVT06 could prove a key swing factor that either eases balance sheet concerns or keeps funding risk in focus.

Explore 5 other fair value estimates on Alvotech - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.